← Back to Search

Monoclonal Antibodies

PRL3-zumab for Solid Tumors

Phase 2
Recruiting
Research Sponsored by Intra-IMMUSG Pte Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day.
Awards & highlights

Study Summary

This trial is testing a new drug for cancer that has not been treated before. It is open to people with cancer that has spread or cannot be removed by surgery.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day.
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-dose and during first dose of c1, pre dose c1d15, c2d1, c2d15, c3d1, and pre dose and during the second dose of c3, pre-dose c4d1, c5d1, c6d1 and at end of treatment (up to approximately 6 months). duration of 1 cycle is 4 weeks. c = cycle, d = day. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Clinical benefit rate (CBR)
Duration of response
Objective response rate (ORR)
+2 more
Secondary outcome measures
Area under the concentration time curve from pre-dose (AUCinf)
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
European Organization for Research and Treatment of Cancer-quality of life quantionnaire-C30 (EORTC-QLQ-C30)
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRL3-zumabExperimental Treatment1 Intervention
All patients will receive PRL3-zumab until clinical progression per RECIST v1.1 and iRECIST criteria, or unacceptable toxicity, or withdraws consent.

Find a Location

Who is running the clinical trial?

ParexelIndustry Sponsor
303 Previous Clinical Trials
100,771 Total Patients Enrolled
Intra-IMMUSG Pte LtdLead Sponsor

Media Library

PRL3-zumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04452955 — Phase 2
Solid Tumors Research Study Groups: PRL3-zumab
Solid Tumors Clinical Trial 2023: PRL3-zumab Highlights & Side Effects. Trial Name: NCT04452955 — Phase 2
PRL3-zumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04452955 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
2020. "A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04452955.
~13 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top